T
Teemu T. Junttila
Researcher at Genentech
Publications - 50
Citations - 5123
Teemu T. Junttila is an academic researcher from Genentech. The author has contributed to research in topics: T cell & Cancer. The author has an hindex of 29, co-authored 47 publications receiving 4577 citations. Previous affiliations of Teemu T. Junttila include University of Turku.
Papers
More filters
Journal ArticleDOI
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila,Robert W. Akita,Kathryn Parsons,Carter Fields,Gail Lewis Phillips,Lori Friedman,Deepak Sampath,Mark X. Sliwkowski +7 more
TL;DR: A mechanism of action for trastuzumab whereby antibody treatment disrupts ligand-independent HER2/HER3 interactions in HER2-amplified cells is described, leading to downregulation of proximal and distal AKT signaling, and correlates with the antiproliferative effects of trastzumab.
Journal ArticleDOI
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
Minna Tanner,Maija Hollmén,Teemu T. Junttila,A. I. Kapanen,S. Tommola,Y. Soini,H. Helin,J. Salo,Heikki Joensuu,E. Sihvo,Klaus Elenius,Klaus Elenius,Jorma Isola +12 more
TL;DR: HER-2/neu amplification is common in the intestinal type of gastric carcinoma, and it is associated with a poor outcome, and this hypothesis deserves to be investigated in clinical trials.
Journal ArticleDOI
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
TL;DR: T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors and in patients whose breast tumors overexpress HER2/ErbB2.
Journal ArticleDOI
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
Kaisa Erjala,Maria Sundvall,Teemu T. Junttila,Na Zhang,Mika Savisalo,Pekka Mali,Jarmo Kulmala,Jaakko Pulkkinen,Reidar Grénman,Klaus Elenius +9 more
TL;DR: EGFR amplification may predict sensitivity to gefitinib in HNSCC, however, other EGFR/ErbB receptor family members than EGFR may contribute to resistance to g EFITinib.
Journal Article
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
Minna Tanner,Anita I Kapanen,Teemu T. Junttila,Olayinka Raheem,Seija Grénman,Jussi Elo,Klaus Elenius,Jorma Isola +7 more
TL;DR: The JIMT-1 cell line provides a valuable experimental model for studies of new trastuzumab-resistance mechanisms and is phenotypically of epithelial progenitor cell origin, as evidenced by immunohistochemical positivity for both cytokeratins 5/14 and 8/18.